After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!
Text Size:AAA

MERS-CoV (HCoV-EMC/2012) Spike Protein (ECD, aa 1-1297, His Tag)

DatasheetSpecific ReferencesReviewsRelated ProductsProtocols
SpikeProtein Product Information
Protein Construction:A DNA sequence encoding the extracellular domain of spike protein (Human betacoronavirus 2c EMC/2012)( AFS88936.1) (Met1-Trp1297) was fused with a polyhistidine tag at the C-terminus.
Expressed Host:Baculovirus-Insect Cells
Form & Shipping:In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
SpikeProtein QC Testing
Purity:> 85 % as determined by SDS-PAGE
Bio-Activity:1. Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC). The specific activity is > 2,500 pmoles/min/μg.
2. Using the Octet RED System, the affinity constant (Kd) of human DPP4 (Cat: 10688-HNCH) bound to Spike (HCoV-EMC/2012) (Cat: 40071-V31B) was 20 nM.
3. Using the Octet RED System, the affinity constant (Kd) of human DPP4 (Cat: 10688-HNCH) bound to Spike (HCoV-EMC/2012) (Cat: 40071-V05B) was 50 nM.
4. Using the Octet RED System, the affinity constant (Kd) of human DPP4 (Cat: 10688-HNCH) bound to Spike (HCoV-EMC/2012) (ECD, aa 1-1297) (Cat: 40069-V08B) was 33 nM.
5. Using the Octet RED System, the affinity constant (Kd) of human DPP4 (Cat: 10688-HNCH) bound to Spike-His (aa 1-760) (Cat: 40021-V08H) was 12 nM.
Endotoxin:< 1.0 EU per μg of the protein as determined by the LAL method
Stability:Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N Terminal:Tyr 18
Molecule Mass:The recombinant extracellular domain of spike protein (Human betacoronavirus 2c EMC/2012) comprises 1289 amino acids and has a predicted molecular mass of 142.2 kDa. It migrates as an approximately 157 kDa band in SDS-PAGE under reducing conditions.
Formulation:Lyophilized from sterile 20mM Tris, 500mM Nacl, pH 7.4, 10% glycerol.
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
SpikeProtein Usage Guide
Storage:Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution:A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. 

  • Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
  • Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
  • Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.
  • Related Products
    Product nameProduct name